ストックスクリーナーアプリを入手
78.62
0.99%
0.77
アフターアワーズ：
77.50
-1.12
-1.42%
前日終値:
$77.85
開ける：
$77.53
24時間の取引高:
723.14K
Relative Volume:
0.66
時価総額：
$4.89B
収益：
$209.18M
当期純損益:
$52.04M
株価収益率:
110.34
EPS:
0.7125
ネットキャッシュフロー:
$37.10M
1週間 パフォーマンス:
+5.02%
1か月 パフォーマンス:
+18.35%
6か月 パフォーマンス:
+71.58%
1年 パフォーマンス:
+71.51%
1日の値動き範囲:
$76.66
$79.01
1週間の範囲:
$74.03
$79.01
52週間の値動き範囲:
$33.31
$93.25
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
名前
Protagonist Therapeutics Inc
セクター
電話
(510) 474-0170
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
78.62 | 4.84B | 209.18M | 52.04M | 37.10M | 0.7125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-12 | 開始されました | Leerink Partners | Outperform |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-12-06 | 開始されました | Goldman | Neutral |
| 2024-11-05 | 開始されました | Wedbush | Outperform |
| 2024-09-24 | 開始されました | TD Cowen | Buy |
| 2024-09-09 | 開始されました | Truist | Buy |
| 2023-10-30 | 開始されました | CapitalOne | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-11 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-24 | 開始されました | Northland Capital | Outperform |
| 2021-01-06 | 開始されました | JP Morgan | Overweight |
| 2020-12-16 | 開始されました | Piper Sandler | Overweight |
| 2020-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | 開始されました | Jefferies | Buy |
| 2020-05-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-09 | アップグレード | Stifel | Hold → Buy |
| 2018-12-06 | 開始されました | Nomura | Buy |
| 2018-01-29 | 開始されました | Stifel | Buy |
| 2017-07-21 | 開始されました | BTIG Research | Buy |
すべてを表示
Protagonist Therapeutics Inc (PTGX) 最新ニュース
How strong is Protagonist Therapeutics Inc. stock revenue growth2025 Momentum Check & Safe Capital Preservation Plans - newser.com
Price action breakdown for Protagonist Therapeutics Inc.July 2025 Recap & Free Fast Gain Swing Trade Alerts - newser.com
Is Protagonist Therapeutics Inc. stock entering bullish territoryStop Loss & Long-Term Safe Investment Ideas - newser.com
Can Protagonist Therapeutics Inc. hit a new high this month2025 Dividend Review & Weekly Market Pulse Updates - newser.com
Is Protagonist Therapeutics Inc. stock a top pick in earnings season2025 Momentum Check & Weekly Return Optimization Alerts - newser.com
Protagonist Therapeutics, Inc. $PTGX is Moody Aldrich Partners LLC's 2nd Largest Position - MarketBeat
How Protagonist Therapeutics Inc. stock responds to policy changes2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Donaldsonville Chief
What is Wedbush's Estimate for PTGX FY2029 Earnings? - MarketBeat
Protagonist Therapeutics Inc. stock chart pattern explained2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Protagonist Therapeutics (PTGX) to Release Earnings on Thursday - MarketBeat
How rising interest rates impact Protagonist Therapeutics Inc. stock2025 Breakouts & Breakdowns & Safe Investment Capital Preservation Plans - newser.com
Will Protagonist Therapeutics Inc. stock benefit from commodity pricesProduct Launch & Daily Entry Point Alerts - newser.com
How Protagonist Therapeutics Inc. stock reacts to job market data2025 Market Outlook & Expert Curated Trade Setups - newser.com
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - Asbury Park Press
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
How to track smart money flows in Protagonist Therapeutics Inc.2025 Retail Activity & Risk Controlled Daily Trade Plans - newser.com
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $86.00 at Wedbush - MarketBeat
Protagonist Therapeutics (PTGX) Price Target Increased by 10.06% to 78.69 - Nasdaq
BTIG Research Reiterates "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
State of New Jersey Common Pension Fund D Sells 12,711 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Wedbush Maintains Protagonist Therapeutics (PTGX) Outperform Recommendation - Nasdaq
Protagonist Therapeutics (PTGX): Truist Securities Raises Price Target to $88 | PTGX Stock News - GuruFocus
PTGX: Wedbush Raises Price Target to $86, Maintains Outperform R - GuruFocus
Wedbush Raises Price Target on Protagonist Therapeutics to $86 From $70, Keeps Outperform Rating - MarketScreener
What 7 Analyst Ratings Have To Say About Protagonist Therapeutics - Benzinga
PTGX Maintains 'Buy' Rating with Price Target Steady at $82.00 | - GuruFocus
Protagonist Therapeutics Inc (PTGX) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):